NeuroSearch signs Beckman Coulter diagnostics agreement
An agreement has been signed between Beckman Coulter and NeuroSearch.
NeuroSearch has announced that business negotiations between it and Beckman Coulter have resulted in an agreement being signed.
The pair have set out plans to work together in developing innovation in the field, with the expressed intent of creating new diagnostic testing systems.
NeuroSearch, a Danish pharmacy specialist, announced that the agreement will see subsidiary corporation Atonomics team up with Beckman Coulter to further their ends in the fields of cardiovascular diseases and prostate cancer.
Commenting on the signing, Patrik Dahlen, chief executive officer for NeuroSearch, expressed his approval of the move.
"We see the agreement with Beckman Coulter as a seal of approval of the technology and the commercial potential. This deal is also an important step towards the overall strategy of NeuroSearch of exploiting the values of our associated companies," he said.
Similar comments were issued by Richard Creager, group vice-president of Immunoassay and Molecular Diagnostics for Beckman Coulter, who said his firm was "extremely pleased" with the outcome of business negotiations.
This comes after Synthes revealed it would be merging with healthcare giant Johnson and Johnson.